Skip to main content
. Author manuscript; available in PMC: 2023 Feb 3.
Published in final edited form as: Breast Cancer Res Treat. 2022 Feb 3;192(1):153–161. doi: 10.1007/s10549-021-06475-2

Figure 4. SF-36 Physical functioning score by treatment group and time point.

Figure 4.

Adjusted least-square mean scores for all timepoints after baseline are obtained from mixed model for repeated measures analysis of the score.

AC, doxorubicin and cyclophosphamide; FEC-100, 5-fluorouracil, epirubicin and cyclophosphamide.

Footnote: *statistically significant differences observed: Day 1: FEC-100:66.97; AC:69.86, difference=−2.90, 95%CI=(−5.15, −0.65), P value=0.01; 6 months: FEC-100:71.40; AC:77.44, difference=−6.04, 95%CI=(−8.32, −3.77), P value<0.001; and 12 months: FEC-100:75.94; AC:79.29, difference=−3.35, 95%CI=(−5.64, −1.06), P value=0.004.